Processa Pharmaceuticals, Inc. (PCSA) Balance Sheet
PCSA balance sheet, 2025
December 31, 2025 · U.S. dollars$7.8M assets = $2.2M liabilities + $5.6M equity
Both columns are drawn to the same scale: what PCSA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
PCSA financial health
Descriptive bands, not a rating. Fiscal 2025.
PCSA balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $104,3212016 | $7.8M2025 | +61.5%/yr | |
| Total liabilities | $2.1M2016 | $2.2M2025 | +0.8%/yr | |
| Shareholders’ equity | −$2.0M2016 | $5.6M2025 | — | |
| Cash & short-term investments | $2,0902016 | $5.5M2025 | +140.1%/yr | |
| Total debt | $1.4M2016 | $73,5072024 | −30.6%/yr | |
| Net cash (debt) | −$1.4M2016 | $1.1M2024 | +$2.5M | |
| Working capital | −$2.0M2016 | $3.4M2025 | +$5.4M | |
| Current ratio | 0.052016 | 2.542025 | +2.49 | |
| Debt / equity | 6.562017 | 0.042024 | −6.52 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PCSA assets
PCSA liabilities and equity
PCSA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
PCSA balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $5.5M | $1.2M | $4.7M | $6.5M | $16.5M | $15.4M | $691,536 | $1.7M | $2.8M | $2,090 |
| Cash & equivalents | $5.5M | $1.2M | $4.7M | $6.5M | $16.5M | $15.4M | $691,536 | $1.7M | $2.8M | $2,090 |
| Short-term investments | — | — | — | — | — | — | — | $0 | $1.0M | $1.0M |
| Receivables | $0 | $0 | $0 | $0 | $70,274 | $231,754 | $0 | $21,583 | $62,709 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $133,919 | $682,294 | $926,300 | $1.9M | $1.8M | $554,708 | $315,605 | $257,832 | $41,446 | $102,072 |
| Total current assets | $5.7M | $1.9M | $5.6M | $8.4M | $18.3M | $16.2M | $1.0M | $2.0M | $3.0M | $104,162 |
| Property, plant & equipment (net) | $3,812 | $75,693 | $148,611 | $227,587 | $74,181 | $159,042 | $228,004 | $17,375 | $25,821 | $159 |
| Goodwill & intangible assets | $1.1M | $0 | $0 | $0 | $8.1M | $8.8M | $9.6M | $10.4M | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $993,701 | $1.3M | $5,535 | $5,535 | $5,535 | $5,535 | $5,535 | $739,096 | $5,535 | $0 |
| Total assets | $7.8M | $3.2M | $5.8M | $8.6M | $26.5M | $25.2M | $10.9M | $13.2M | $3.0M | $104,321 |
| Liabilities | ||||||||||
| Accounts payable | $1.1M | $880,880 | $311,617 | $327,548 | $218,905 | $320,694 | $75,612 | $292,102 | $50,686 | $159,249 |
| Short-term debt | — | $73,020 | $83,649 | $78,896 | $71,078 | $204,774 | $880,495 | $230,000 | $2.4M | $1.4M |
| Deferred revenue | — | — | — | — | — | — | — | — | $483,907 | $257,147 |
| Total current liabilities | $2.2M | $1.5M | $730,579 | $998,556 | $971,020 | $1.2M | $1.2M | $645,704 | $2.6M | $2.1M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $44,885 | $0 | $0 | $0 | $0 |
| Lease obligations | $0 | $73,507 | $150,554 | $229,450 | $78,463 | $165,663 | $225,382 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $487 | $66,905 | $150,554 | $7,385 | $1.0M | $1.7M | $2.1M | $9,963 | $0 |
| Total liabilities | $2.2M | $1.5M | $797,484 | $1.1M | $978,405 | $2.3M | $2.9M | $3.5M | $2.6M | $2.1M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $257 | $371 | $129 | $1,614 | $1,571 | $1,419 | $549 | $3,867 | $3,527 | $1,102 |
| Retained earnings (deficit) | −$100.8M | −$87.2M | −$75.4M | −$64.2M | −$36.8M | −$25.4M | −$11.0M | −$7.6M | −$3.9M | −$14.9M |
| Treasury stock | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Accumulated other comprehensive income | — | $0 | $0 | $0 | $0 | — | $0 | −$1.8M | −$3,246 | −$18,991 |
| Minority interest | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Total shareholders' equity | $5.6M | $1.7M | $5.0M | $7.5M | $25.5M | $22.9M | $8.0M | $9.7M | $373,164 | −$2.0M |
| Key figures | ||||||||||
| Total debt | — | $73,507 | $150,554 | $229,450 | $78,463 | $328,122 | $1.0M | $230,000 | $2.4M | $1.4M |
| Net cash (debt) | — | $1.1M | $4.6M | $6.3M | $16.4M | $15.1M | −$336,349 | $1.5M | $398,859 | −$1.4M |
| Working capital | $3.4M | $340,988 | $4.9M | $7.4M | $17.4M | $15.0M | −$184,423 | $1.4M | $351,771 | −$2.0M |
| Tangible book value | $4.4M | $1.7M | $5.0M | $7.5M | $17.4M | $14.1M | −$1.6M | −$736,764 | $373,164 | −$2.0M |
| Book value per share | $4.26 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 1.3M | — | — | — | — | — | — | — | — | — |
| Current ratio | 2.54 | 1.22 | 7.71 | 8.40 | 18.87 | 13.27 | 0.85 | 3.13 | 1.14 | 0.05 |
| Quick ratio | 2.48 | 0.78 | 6.44 | 6.51 | 17.06 | 12.82 | 0.58 | 2.73 | 1.12 | 0.00 |
| Debt / equity | — | 0.04 | 0.03 | 0.03 | 0.00 | 0.01 | 0.13 | 0.02 | 6.56 | — |
| Equity / assets | 71.4% | 52.5% | 86.2% | 86.7% | 96.3% | 91.0% | 73.6% | 73.4% | 12.5% | −1,896.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $196,325 | $1.7M | $5.5M | $6.3M | $6.9M | $2.9M | $1.2M | $2.9M | $5.6M | $8.9M | $4.7M | $6.9M |
| Cash & equivalents | $196,325 | $1.7M | $5.5M | $6.3M | $6.9M | $2.9M | $1.2M | $2.9M | $5.6M | $8.9M | $4.7M | $6.9M |
| Short-term investments | $472,003 | — | — | — | — | — | — | — | — | — | — | — |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $22,295 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $1.9M | $247,363 | $133,919 | $278,342 | $217,201 | $860,814 | $682,294 | $1.9M | $1.9M | $857,635 | $926,300 | $1.0M |
| Total current assets | $2.1M | $1.9M | $5.7M | $6.6M | $7.2M | $3.8M | $1.9M | $4.8M | $7.5M | $9.8M | $5.6M | $7.9M |
| Property, plant & equipment (net) | $3,210 | $3,511 | $3,812 | $4,113 | $28,732 | $52,452 | $75,693 | $98,478 | $117,467 | $138,904 | $148,611 | $169,729 |
| Goodwill & intangible assets | $0 | $1.6M | $1.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $993,701 | $993,701 | $993,701 | $999,236 | $999,236 | $1.3M | $5,535 | $5,535 | $5,535 | $5,535 | $5,535 |
| Total assets | $2.1M | $4.5M | $7.8M | $7.6M | $8.2M | $4.8M | $3.2M | $4.9M | $7.6M | $9.9M | $5.8M | $8.1M |
| Liabilities | ||||||||||||
| Accounts payable | $1.7M | $840,370 | $1.1M | $727,172 | $785,754 | $552,560 | $880,880 | $711,710 | $953,086 | $455,368 | $311,617 | $346,299 |
| Short-term debt | — | — | — | — | $25,584 | $49,659 | $73,020 | $94,676 | $93,181 | $89,680 | $83,649 | $82,744 |
| Total current liabilities | $2.4M | $2.0M | $2.2M | $1.8M | $2.1M | $1.3M | $1.5M | $1.2M | $1.6M | $1.0M | $730,579 | $826,070 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | — | $0 | $0 | $25,584 | $49,659 | $73,507 | $96,844 | $118,829 | $140,380 | $150,554 | $171,521 |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $487 | $2,168 | $25,648 | $50,700 | $66,905 | $88,777 |
| Total liabilities | $2.4M | $2.0M | $2.2M | $1.8M | $2.1M | $1.3M | $1.5M | $1.2M | $1.6M | $1.1M | $797,484 | $914,847 |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $279 | $269 | $257 | $5,287 | $4,029 | $527 | $371 | $327 | $287 | $286 | $129 | $2,473 |
| Retained earnings (deficit) | −$107.4M | −$104.2M | −$100.8M | −$97.4M | −$94.0M | −$90.1M | −$87.2M | −$84.5M | −$81.1M | −$78.1M | −$75.4M | −$73.0M |
| Accumulated other comprehensive income | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total shareholders' equity | −$317,341 | $2.5M | $5.6M | $5.8M | $6.1M | $3.5M | $1.7M | $3.7M | $6.0M | $8.9M | $5.0M | $7.2M |
| Key figures | ||||||||||||
| Total debt | — | — | — | — | $25,584 | $49,659 | $73,507 | $96,844 | $118,829 | $140,380 | $150,554 | $171,521 |
| Net cash (debt) | — | — | — | — | $6.9M | $2.8M | $1.1M | $2.8M | $5.5M | $8.8M | $4.6M | $6.7M |
| Working capital | −$320,551 | −$41,687 | $3.4M | $4.8M | $5.1M | $2.5M | $340,988 | $3.6M | $5.9M | $8.8M | $4.9M | $7.1M |
| Tangible book value | −$317,341 | $955,525 | $4.4M | $5.8M | $6.1M | $3.5M | $1.7M | $3.7M | $6.0M | $8.9M | $5.0M | $7.2M |
| Book value per share | −$0.12 | $0.97 | $2.17 | $3.07 | $9.81 | — | — | — | — | — | — | — |
| Shares outstanding | 2.8M | 2.6M | 2.6M | 1.9M | 623K | — | — | — | — | — | — | — |
| Current ratio | 0.87 | 0.98 | 2.54 | 3.76 | 3.45 | 2.93 | 1.22 | 3.97 | 4.82 | 9.70 | 7.71 | 9.57 |
| Quick ratio | 0.08 | 0.85 | 2.48 | 3.60 | 3.34 | 2.26 | 0.78 | 2.37 | 3.59 | 8.85 | 6.44 | 8.31 |
| Debt / equity | — | — | — | — | 0.00 | 0.01 | 0.04 | 0.03 | 0.02 | 0.02 | 0.03 | 0.02 |
| Equity / assets | −15.3% | 56.2% | 71.4% | 76.9% | 74.6% | 73.3% | 52.5% | 75.3% | 79.2% | 89.3% | 86.2% | 88.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 18, 2026); data from EODHD.
PCSA financial position
At the end of fiscal 2025 (December 31, 2025), Processa Pharmaceuticals had total assets of $7.8 million (up 142.0% from a year earlier), total liabilities of $2.2 million and shareholders' equity of $5.6 million. Its current ratio was 2.54. In the latest quarter (ended June 30, 2026) total assets were $2.1 million and equity -$0.3 million.
Related: PCSA income statement, PCSA cash flow statement, PCSA key metrics. See the PCSA stock overview for the latest quote and news.
PCSA balance sheet FAQ
What are Processa Pharmaceuticals's total assets?
Processa Pharmaceuticals reported total assets of $7.8 million at the end of fiscal 2025 (December 31, 2025), compared with $3.2 million a year earlier.
How much cash does Processa Pharmaceuticals have?
Processa Pharmaceuticals held $5.5 million in cash and short-term investments at the end of fiscal 2025.
What is Processa Pharmaceuticals's book value?
Processa Pharmaceuticals's shareholders' equity (book value) was $5.6 million at the end of fiscal 2025, or $4.26 per share.
What is Processa Pharmaceuticals's current ratio?
Processa Pharmaceuticals had current assets of $5.7 million and current liabilities of $2.2 million, a current ratio of 2.54 (it can cover its short-term obligations).
How much goodwill does Processa Pharmaceuticals have?
Processa Pharmaceuticals carried $1.1 million of goodwill and intangible assets, 14.7% of total assets, at the end of fiscal 2025.